Ex-vivo co-blockade of CD-155/TIGIT and PD-1/PD-L1 using CCAT-1, H19 and MALAT-1 LncRNAs in hepatocellular carcinoma

被引：3

作者：

Youness, R. A. ^{[1
]}

Gomaa, A. ^{[2
]}

机构：

[1] Univ Hertfordshire Hosted Global Acad Fdn, Sch Life & Med Sci, New Cairo, Egypt

[2] Natl Liver Inst, Hepatol Dept, Sheben Elkom, Egypt

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.10.147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

128P

引用

页码：S1433 / S1433

页数：1

共 40 条

[1] A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma
Assal, Reem A.
Elemam, Noha M.
Mekky, Radwa Y.
Attia, Abdelrahman A.
Soliman, Aya Hesham
Gomaa, Asmaa Ibrahim
Efthimiadou, Eleni K.
Braoudaki, Maria
Fahmy, Sherif Ashraf
Youness, Rana A.
TRANSLATIONAL ONCOLOGY, 2024, 45
[2] TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma
Ge, Zhouhong
Zhou, Guoying
Carrascosa, Lucia Campos
Gausvik, Erik
Boor, Patrick P. C.
Noordam, Lisanne
Doukas, Michael
Polak, Wojciech G.
Terkivatan, Turkan
Pan, Qiuwei
Takkenberg, R. Bart
Verheij, Joanne
Erdmann, Joris, I
IJzermans, Jan N. M.
Peppelenbosch, Maikel P.
Kraan, Jaco
Kwekkeboom, Jaap
Sprengers, Dave
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2021, 12 (02): : 443 - 464
[3] THE TIGIT/CD226/CD155 AXIS AND THE EFFECTS OF COMBINING PD-1/PD-L1 BLOCKADE WITH TIGIT-TARGETING ANTIBODY THERAPY IN SYNGENEIC MURINE GLIOBLASTOMA MODELS
Gokhale, Prafulla
Iorgulescu, Bryan
Klapholz, Max
Poitras, Michael
Eschle, Benjamin
Freeman, Gordon
Anderson, Ana
Reardon, David
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A277 - A278
[4] Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma
Yu-Yun Shao
Han-Yu Wang
Hung-Wei Hsu
Rita Robin Wo
Ann-Lii Cheng
Chih-Hung Hsu
Biology Direct, 20 (1)
[5] Characterize the Tissue Biodistribution of PD-1, PD-L1, and CD19 mRNA in Lung Carcinoma
Chandel, Nirupama
Mazzoni, Francesca
Tian, Kui
Coleman, Jack
MOLECULAR THERAPY, 2024, 32 (04) : 610 - 610
[6] Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma
Nishida, Naoshi
HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (05) : 640 - 643
[7] DUAL TARGETING OF CD155/TIGIT AND PD-L1/PD-1 IMMUNE CHECKPOINTS POTENTIATES NATURAL KILLER CELL-MEDIATED CYTOTOXICITY IN MEDULLOBLASTOMA
Monnikhof, Matthijs
Schakelaar, Michael
Meulenbroeks, Chris
Quist, Matthias
Perzolli, Alicia
Selten, Aimee
Koster, Celeste
Maassen, Danielle
Canelo, Alba Montoro
Fredriks, Maureen
Kaludjerovic, Vela
Meeldijk, Jan
Pijnappel, Emma
Rebel, Heggert
van Kempen, Sven
Crnko, Sandra
Frederico, Aniello
Wesseling, Pieter
Calkoen, Friso
van der Lugt, Jasper
ten Broeke, Toine
Kool, Marcel
Bovenschen, Niels
NEURO-ONCOLOGY, 2024, 26
[8] Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Hua-Yu Yang
Le-Jia Sun
Yi-Lei Mao
Hepatobiliary & Pancreatic Diseases International, 2018, 17 (02) : 93 - 94
[9] Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang, Hua-Yu
Sun, Le-Jia
Mao, Yi-Lei
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2018, 17 (02) : 93 - 94
[10] Self-supervised contrastive learning using CT images for PD-1/PD-L1 expression prediction in hepatocellular carcinoma
Xie, Tianshu
Wei, Yi
Xu, Lifeng
Li, Qian
Che, Feng
Xu, Qing
Cheng, Xuan
Liu, Minghui
Yang, Meiyi
Wang, Xiaomin
Zhang, Feng
Song, Bin
Liu, Ming
FRONTIERS IN ONCOLOGY, 2023, 13

← 1 2 3 4 →